GlobeNewswire 2015-06-02Company Announcement -- Exclusive license from Bristol-Myers Squibb for human antibodies against CD19 target --... ...http://www.bizwireexpress.com/showstoryGNW.php?storyid=73232
PharmaMar, one of the world-leading biopharmaceutical company in advancing cancer care through the discovery and development of innovative... ...http://www.pharmabiz.com/NewsDetails.aspx?aid=88622&sid=2
/PRNewswire/ --Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR)... ...http://in.advfn.com/p.php?pid=nmona&article=67103272
Single-Agent Selinexor Demonstrates Broad and Durable Anti- tumor Activity and Disease Control and Tolerability in Clinical Studies NEWTON,... ...http://www.bizwireexpress.com/showstoryGNW.php?storyid=73190
A large cooperative-group study has confirmed previous evidence that lenalidomide delays time to disease progression for patients with multiple... ...http://health.infrosoft.com/index.php?page=news&op=readNews&id=53191&title=Phase-III-Study-Confirms-Benefits-of-Lenalidomide-Maintenance-Therapy-for-Patients-with-Multiple-Myeloma
Multiple myeloma also called myeloma...